The estimated Net Worth of Tomer Pontifax (Israel) V, ... is at least $2.03 Millón dollars as of 11 November 2019. Tomer V owns over 250,000 units of 89bio Inc stock worth over $2,027,500 and over the last 5 years Tomer sold ETNB stock worth over $0.
Tomer has made over 1 trades of the 89bio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Tomer bought 250,000 units of ETNB stock worth $4,000,000 on 11 November 2019.
The largest trade Tomer's ever made was buying 250,000 units of 89bio Inc stock on 11 November 2019 worth over $4,000,000. On average, Tomer trades about 250,000 units every 0 days since 2019. As of 11 November 2019 Tomer still owns at least 250,000 units of 89bio Inc stock.
You can see the complete history of Tomer V stock trades at the bottom of the page.
Over the last 5 years, insiders at 89bio Inc have traded over $17,267,666 worth of 89bio Inc stock and bought 14,519,952 units worth $208,678,684 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... y Advisors Llc Orbi Med Capit.... On average, 89bio Inc executives and independent directors trade stock every 28 days with the average trade being worth of $2,197,340. The most recent stock trade was executed by Rohan Palekar on 1 April 2024, trading 52,718 units of ETNB stock currently worth $575,153.
89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.
89bio Inc executives and other stock owners filed with the SEC include: